News & Events

 | Press Releases
   

2010 Archive

2009 Archive

2008 Archive

2007 Archive

2006 Archive

2005 Archive

 

RESULT OF AGM, LOAN CONVERSION AND TOTAL VOTING RIGHTS

30th June 2010

Proteome Sciences is pleased to announce that, at the Company's Annual General Meeting (the "AGM") held earlier today all resolutions were duly passed.

The Company is also pleased to announce that following approval by shareholders at the Company's AGM, the conversion has now taken place of £5 million of the loan provided to the Company by Christopher Pearce, Chief Executive, into 25,000,000 ordinary shares of 1 pence each ("Ordinary Shares") (the "Loan Conversion"). The Loan Conversion was done at 20 pence per share, representing the placing price of the firm placing (the "Firm Placing") and open offer (the "Open Offer") which together raised £6.9 million before expenses. The Firm placing and Open Offer completed on 18 June and 28 June respectively.

Following the Loan Conversion, Christopher Pearce is interested in 31,538,075 Ordinary Shares representing 16.41 per cent. of the Company's issued share capital.

Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 25,000,000 new Ordinary Shares. It is expected that Admission will become effective on 1 July 2010. The new Ordinary Shares, when issued and fully paid will rank equally in all respects with the Existing Ordinary Shares, including the right to receive all dividends or other distributions made, paid or declared.

Following the Firm Placing, Open Offer and Loan Conversion the Company's issued share capital will consist of 192,172,408 Ordinary Shares, with voting rights (one vote per ordinary share). The Company does not hold any ordinary shares in Treasury.

Therefore, the total number of Ordinary Shares in the Company with voting rights is 192,172,408.

The above figure of 192,172,408 ordinary shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.



Site last updated:22nd July, 2010

Back

© Proteome Sciences 2009

Company Profile
Company Profile
Disease Focus
Technologies
Products
Collaborations
News & Events
Contact
Rule 26
Homepage